Acne is a chronic inflammatory skin disease that affects the quality of life of patients. Several treatments exist for acne, but their effectiveness tends to decrease over time due to increasing resistance to treatment and associated side effects. To circumvent these issues, a new approach has emerged that involves combating the pathogen Cutibacterium acnes while maintaining the homeostasis of the skin microbiome. Recently, it was shown that the use of a G2 lysine dendrigraft (G2 dendrimer) could specifically decrease the C. acnes phylotype (IAI) involved in acne, compared to non-acne-causing C. acnes (phylotype II) bacteria. In the present study, we demonstrate that the efficacy of this technology is related to its 3D structure, which, in contrast to the linear form, significantly decreases the inflammation factor (IL-8) linked to acne. In addition, our in-vitro data confirm the specific activity of the G2 dendrimer: after treatment of bacterial cultures and biofilms, the G2 dendrimer affected neither non-acneic C. acnes nor commensal bacteria of the skin (Staphylococcus epidermidis, S. hominis, and Corynebacterium minutissimum). In parallel, comparative in-vitro and in-vivo studies with traditional over-the-counter molecules showed G2’s effects on the survival of commensal bacteria and the reduction of acne outbreaks. Finally, metagenomic analysis of the cutaneous microbiota of volunteers who applied a finished cosmetic product containing the G2 dendrimer confirmed the ability of G2 to rebalance cutaneous acne microbiota dysbiosis while maintaining commensal bacteria. These results confirm the value of using this G2 dendrimer to gently prevent the appearance of acne vulgaris while respecting the cutaneous microbiota.

The skin is exposed to environmental aggressions and its stratum corneum (SC) plays a role in the barrier function (BF) which is critical for skin homeostasis. The maintain of this BF is important to avoid exogenous pathogen penetration and skin inflammation leading to the risk of developing allergic disease as atopic dermatitis (AD). Proteins of the Late Cornified Envelope (LCE)

Wound healing dysregulation often results in visible scarring with significant psychological impact, particularly affecting individuals with darker skin phototypes. This study investigates the efficacy of an aqueous extract of Australian Jellybush honey (Leptospermum polygalifolium) in improving scar appearance across diverse skin tones. Our research demonstrated the extract reduced IL-8 production by 42%, decreased reactive oxygen species by 14.6%, and increased pro-collagen I synthesis by 28%. Ex vivo experiments revealed a 44% increase in neo-epidermal tongue length after 10 days while gene expression analysis showed coordinated wound healing through timed modulation of key markers such as filaggrin, matrix metalloproteases, keratins. In a double-blind clinical study involving 21 volunteers (phototypes II–VI) with acne scars, 8-week application of 2% Jellybush honey extract improved skin homogeneity by 15%, reduced scar surface area by 3% and decreased atrophic and hypertrophic scars dimensions by 9% and 16%, respectively, versus placebo. These improvements were consistent across all phototypes, including V-VI. Jellybush honey extract offers a promising approach for scar management through balanced modulation of wound healing pathways across all skin phototypes.